Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Amyloid-related imaging abnormalities (ARIAs) are among the most important safety considerations during lecanemab treatment for Alzheimer's disease (AD). Although APOE ε4 carrier status is a recognized ARIA risk factor, the relationship between ARIAs and routine demographic and clinical characteristics in real-world practice remains incompletely characterized. This study evaluated demographic, vascular comorbidity, and APOE genotype characteristics among patients treated with lecanemab, stratified by ARIA status. Methodology We conducted a retrospective cohort study of patients with AD treated with lecanemab at a single academic institution from December 4, 2023, to October 28, 2025. Of 324 identified patients, 318 were included in the primary analysis. Demographic and clinical variables were extracted from the electronic health record. ARIA status and subtype were determined from clinical MRI interpretations by board-certified neuroradiologists. Patients were stratified by presence and type of ARIA development during treatment. Results Among 318 included patients, 98 (30.8%) developed ARIA and 220 (69.2%) did not. Among ARIA-positive patients, nine (9.2%) had ARIA-E only, 50 (51.0%) had ARIA-H only, and 39 (39.8%) had mixed ARIA-E/H. Age was similar between ARIA-positive and ARIA-negative patients (74.4 vs. 73.6 years; p = 0.437). ARIAs occurred in 33.9% of female patients and 26.8% of male patients (p = 0.218), and in 52.9% of non-White patients and 29.6% of White non-Hispanic patients (p = 0.078). Hypertension, hyperlipidemia, and diabetes were not associated with ARIA. APOE ε4 carriers had a higher incidence of ARIA than non-carriers (35.3% vs. 22.8%; p = 0.029), although differences across individual APOE genotypes did not reach statistical significance (p = 0.135). Conclusions In this real-world cohort of patients treated with lecanemab, ARIAs occurred in nearly one-third of patients. APOE ε4 carrier status was the only evaluated demographic, clinical, or genetic variable significantly associated with ARIAs. Sex- and race/ethnicity-related differences were exploratory and require validation in larger, more diverse prospective cohorts. These findings support genotype-informed ARIA surveillance while emphasizing the need for broader representation in studies of anti-amyloid therapy safety.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Rohatgi, S., Younan, C. M., Martinez Imbett, R. E., Ford, J. N., Wleklinski, M., Zhu, S., et al. (2026). Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status. Cureus. https://doi.org/10.7759/cureus.114472

Vancouver

Rohatgi S, Younan CM, Martinez Imbett RE, Ford JN, Wleklinski M, Zhu S, et al. Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status. Cureus. 2026. doi:10.7759/cureus.114472. PMID: 42732414.

BibTeX

@article{rohatgi2026-42732414,
  author  = {Rohatgi, S. and Younan, C. M. and Martinez Imbett, R. E. and Ford, J. N. and Wleklinski, M. and Zhu, S. and Romero, J.},
  title   = {{Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status}},
  journal = {Cureus},
  year    = {2026},
  doi     = {10.7759/cureus.114472},
  pmid    = {42732414},
  url     = {https://doi.org/10.7759/cureus.114472}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 66/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 2 of 2; Free to read 2 of 2. 38 of the 58 points it could be judged on, which is 66 of 100. Total 66 of 100.38 of the 58 points we could judge = 66 of 100

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 38 of the 58 points we could judge it on, which is 66 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Cureus)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42732414)
Free to read 2 / 2 Free to read
Points 38 / 58 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 38 of the 58 points we could judge it on is 66 out of 100.
Total 66 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “clinical-characteristics”

4 studies in the library carry the topic tag “clinical-characteristics”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →